To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Cirius TherapeuticsModifying Metabolism - for the Treatment of NASH
Most therapeutics in development for NASH target specific enzymes or receptors that regulate NASH. Cirius is taking a different approach and developing a new class of drugs that work by rebalancing metabolism at its root – through balancing mitochondrial metabolism. MSDC-0602K has the potential to reduce the impact of conditions that produce the metabolic dysregulation that drives insulin resistance and tissue damage.